首页> 外文期刊>Clinical and experimental dermatology >Expression of lumican, a small leucine-rich proteoglycan with antitumour activity, in human malignant melanoma.
【24h】

Expression of lumican, a small leucine-rich proteoglycan with antitumour activity, in human malignant melanoma.

机译:lumican,一种具有抗肿瘤活性的富亮氨酸的小蛋白聚糖,在人类恶性黑色素瘤中的表达。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The family of small leucine-rich proteoglycans (SLRPs), which includes decorin, lumican, biglycan and fibromodulin, constitutes an abundant component of the skin extracellular matrix. We previously demonstrated that human lumican inhibits melanoma growth and progression in a mouse experimental model, by regulating cell migration, proliferation and apoptosis. AIM: The aim of this study was to investigate the expression of lumican and decorin in human malignant melanoma and adjacent peritumoral tissue, to understand better their role in the control of growth and invasion of human melanoma. METHODS: Expression of both proteoglycans was studied by immunohistochemistry using specific antibodies in 34 malignant melanomas, 12 Hutchinson's melanotic freckles and 4 cutaneous metastatic melanomas. RESULTS: We showed that lumican and decorin are located in the dermis and in the peritumoral stroma of malignant melanoma, but are not found in melanoma cells or dense tumour tissue. In the healthy dermis, distant from the tumour, the increasing ratio of lumican to decorin was inversely correlated with the proliferation of the tumour cells (P = 0.035). The comparison of the level of expression of lumican protein in superficial vs. nodular subtypes of malignant melanomas showed a decrease of lumican but not decorin in the peritumoral stroma of nodular subtypes. In the peritumoral stroma, the level of expression of lumican but not decorin decreased significantly (P 0.016) with increasing Clark levels. In addition, immunocytochemical and reverse transcription PCR analyses of malignant melanoma cell lines (A-375, HT-144) and of MRC-5 and dermal fibroblasts from healthy donors in vitro confirmed that dermal fibroblasts are responsible for lumican and decorin synthesis in skin. CONCLUSIONS. Lumican may regulate vertical progression of human malignant melanoma, but further study is necessary to clarify the antitumour mechanism and the downstream signal transduction pathways involved.
机译:背景:包括decorin,lumican,biglycan和fibromodulin在内的富含亮氨酸的小蛋白聚糖(SLRP)家族构成了皮肤细胞外基质的丰富组成部分。我们先前证明了人类lumican通过调节细胞迁移,增殖和凋亡来抑制小鼠实验模型中黑色素瘤的生长和进程。目的:本研究的目的是研究lumican和decorin在人类恶性黑色素瘤和癌旁组织中的表达,以更好地了解它们在控制人类黑色素瘤生长和侵袭中的作用。方法:采用特异性抗体通过免疫组织化学方法研究了34种恶性黑色素瘤,12只Hutchinson氏黑斑雀斑和4只皮肤转移性黑素瘤中两种蛋白聚糖的表达。结果:我们发现lumican和decorin位于恶性黑色素瘤的真皮和肿瘤周围基质中,但在黑色素瘤细胞或致密的肿瘤组织中未发现。在远离肿瘤的健康真皮中,Lumican与Decorin的比例增加与肿瘤细胞的增殖呈负相关(P = 0.035)。恶性黑色素瘤表浅型和结节性亚型中发光蛋白的表达水平比较表明,结节性亚型的瘤周基质中发光蛋白减少,但核心蛋白聚糖没有下降。在肿瘤周围的基质中,随着克拉克水平的提高,卢米肯表达的表达水平显着降低(P 0.016)。此外,对恶性黑色素瘤细胞系(A-375,HT-144)和MRC-5以及健康供体的真皮成纤维细胞进行免疫细胞化学和逆转录PCR分析,证实真皮成纤维细胞负责皮肤中的卢米肯和除芯蛋白合成。结论。 Lumican可能调节人类恶性黑色素瘤的垂直进程,但有必要进一步研究以阐明其抗肿瘤机制和所涉及的下游信号转导途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号